The inner segment/outer segment junction

Wong, Ian Y.; Iu, Lawrence P.; Koizumi, Hideki; Lai, Wico W.

doi:10.1097/icu.0b013e3283524162

Cited by 46 publications

(35 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that the morphology of EZ did not correlate with baseline and final retinal thickness. As observed in many previous studies [38], EZ morphology appears to be a good indicator of photoreceptor function, as it correlates with changes in visual acuity independent of retinal thickness. …”

Section: Discussionsupporting

confidence: 67%

Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors

Maggio

Polito²,

Guerriero³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate anatomical and visual outcomes following intravitreal dexamethasone implantation (Ozurdex) in eyes with visual loss due to macular edema (ME) secondary to retinal vein occlusion (RVO) and to identify predictive factors for improvement in best-corrected visual acuity (BCVA). Methods: We retrospectively analyzed medical records of 43 consecutive eyes with treatment-naïve ME secondary to recent onset RVO treated with repeated Ozurdex injections on a pro re nata basis. Results: The mean follow-up (FU) duration was 14 months (min. 12, max. 22). Both mean BCVA and central macular thickness improved significantly at the end of the FU period (p = 0.0001), and more than 30% of the eyes gained ≥3 lines within 3 months of repeated injections. Presence of foveal serous retinal detachment and macular ischemia were negatively associated with visual outcomes. Improvements were significantly associated with baseline BCVA and the integrity of the ellipsoid zone. No serious adverse events were recorded. Conclusions: In our study population, Ozurdex was a safe and effective therapeutic option for the treatment of ME associated with RVO. The results suggest that a comprehensive approach in the examination of RVO eyes may help to predict which patients are most likely to benefit from the treatment.

show abstract

Section: Discussionsupporting

confidence: 67%

Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors

Maggio

Polito²,

Guerriero³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Some studies have indeed shown a correlation between functional improvement and IS-OS recovery in retinal diseases [41,51]. In the SCORE study, eyes showing improvement in the IS-OS status at 12 months presented larger gains in VA [52].…”

Section: Discussionmentioning

confidence: 99%

Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Chiquet¹,

Bron²,

Straub³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: To compare the visual and anatomical outcomes of patients with macular oedema secondary to retinal vein occlusion (RVO) after a switch from bevacizumab to intravitreal injection of a dexamethasone implant (IVI-DEX) or conversely. Methods: 48 patients - 40 in the antivascular endothelial growth factor (VEGF) DEX sequence (AD group), 8 in the DEX anti-VEGF sequence (DA group) - were included in this multicentre retrospective study and evaluated at baseline, 1, 3, 6 and 12 months after the switch. The outcome measurements were visual acuity (VA) and central macular thickness (CMT) evaluated by spectral domain optical coherence tomography. Patients were defined as ‘good responders' if CMT was ≤ 300 µm after the switch. Results: VA significantly improved at 1 month in the AD group (p = 0.03) but not in the DA group (p = 0.40). CMT decreased significantly in the AD group at 1, 6 and 12 months (p = 0.002, p = 0.005 and p = 0.002, respectively). In the DA group, VA did not change from baseline at any time point, and CMT decreased at 1 month (p = 0.02) but not later on. Conclusions: In patients with macula oedema secondary to RVO, the switch from bevacizumab to IVI-DEX seems more beneficial in terms of short-term VA and long-term reduction of CMT than the DEX anti-VEGF agent sequence.

show abstract

“…6 A semiquantitative approach was sometimes adopted by calculating the percentage of the disruption 7 or by measuring the distances between the different retinal layers. 11 The quantitative analysis of the outer retinal layers is based on the assessment of 2 main parameters: the layers' thicknesses [17][18][19] and the layers' reflectivity. It has also been shown that in central serous chorioretinopathy, there was an elongation of photoreceptor outer segments and decreased thickness of the outer nuclear layer.…”

Section: Until Recently Only a Subjective Analysis Of Thementioning

confidence: 99%

Reflectivity of the Outer Retina on Spectral-Domain Optical Coherence Tomography as a Predictor of Photoreceptor Cone Density

Flores

Debellemanière

Bully

et al. 2015

American Journal of Ophthalmology

View full text Add to dashboard Cite

The inner segment/outer segment junction

Cited by 46 publications

References 80 publications

Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors

Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors

Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Reflectivity of the Outer Retina on Spectral-Domain Optical Coherence Tomography as a Predictor of Photoreceptor Cone Density

Contact Info

Product

Resources

About